It is an important topic given that the therapies targeting IGF1R have been undergoing in clinical trials.[23] In addition, it is unknown theoretically whether targeting IGF1R could sufficiently suppress the initiation and progression of glioma in the native in vivo context, and whether it is specific to tumor cells given the presumption that IGF1R is widely expressed in many cells including normal NSCs and OPCs. The gene discussed is IGF1R; the disease is glioma.